JP2025518487A5 - - Google Patents
Info
- Publication number
- JP2025518487A5 JP2025518487A5 JP2024566322A JP2024566322A JP2025518487A5 JP 2025518487 A5 JP2025518487 A5 JP 2025518487A5 JP 2024566322 A JP2024566322 A JP 2024566322A JP 2024566322 A JP2024566322 A JP 2024566322A JP 2025518487 A5 JP2025518487 A5 JP 2025518487A5
- Authority
- JP
- Japan
- Prior art keywords
- i2moerg
- ime
- i2moert
- i2moerc
- sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340365P | 2022-05-10 | 2022-05-10 | |
| US63/340,365 | 2022-05-10 | ||
| US202263397707P | 2022-08-12 | 2022-08-12 | |
| US63/397,707 | 2022-08-12 | ||
| PCT/US2023/021586 WO2023220087A1 (en) | 2022-05-10 | 2023-05-09 | Oligonucleotide compositions and methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025518487A JP2025518487A (ja) | 2025-06-17 |
| JP2025518487A5 true JP2025518487A5 (enExample) | 2026-04-30 |
Family
ID=88730918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024566322A Pending JP2025518487A (ja) | 2022-05-10 | 2023-05-09 | オリゴヌクレオチド組成物及びその方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240102017A1 (enExample) |
| EP (1) | EP4522180A1 (enExample) |
| JP (1) | JP2025518487A (enExample) |
| KR (1) | KR20250008932A (enExample) |
| CN (1) | CN119451683A (enExample) |
| AU (1) | AU2023269186A1 (enExample) |
| CA (1) | CA3251926A1 (enExample) |
| IL (1) | IL316714A (enExample) |
| MX (1) | MX2024013811A (enExample) |
| WO (1) | WO2023220087A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026036032A1 (en) | 2024-08-09 | 2026-02-12 | Amylyx Pharmaceuticals, Inc. | Formulations containing antisense oligonucleotides targeting calpain-2 |
| WO2026036030A1 (en) | 2024-08-09 | 2026-02-12 | Amylyx Pharmaceuticals, Inc. | Antisense oligonucleotides targeting calpain-2 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7102594A (en) * | 1993-06-09 | 1995-01-03 | Pharmagenics, Inc. | Oligonucleotides which inhibit hiv protease function |
| EP2305813A3 (en) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| AU2003285210B2 (en) * | 2002-12-12 | 2009-10-29 | The Australian National University | Methods and means for modulating cellulose biosynthesis in fiber producing plants |
| US20110117106A1 (en) * | 2008-03-06 | 2011-05-19 | Alice Prince | Uses of calpain inhibitors to inhibit inflammation |
| US20170009304A1 (en) * | 2015-07-07 | 2017-01-12 | Splicingcodes.Com | Method and kit for detecting fusion transcripts |
| EP4279084B1 (en) * | 2015-10-28 | 2025-06-11 | Vertex Pharmaceuticals Inc. | Materials and methods for treatment of duchenne muscular dystrophy |
-
2023
- 2023-05-09 US US18/314,761 patent/US20240102017A1/en active Pending
- 2023-05-09 EP EP23804154.5A patent/EP4522180A1/en active Pending
- 2023-05-09 WO PCT/US2023/021586 patent/WO2023220087A1/en not_active Ceased
- 2023-05-09 KR KR1020247041041A patent/KR20250008932A/ko active Pending
- 2023-05-09 CA CA3251926A patent/CA3251926A1/en active Pending
- 2023-05-09 JP JP2024566322A patent/JP2025518487A/ja active Pending
- 2023-05-09 IL IL316714A patent/IL316714A/en unknown
- 2023-05-09 CN CN202380049889.XA patent/CN119451683A/zh active Pending
- 2023-05-09 AU AU2023269186A patent/AU2023269186A1/en active Pending
-
2024
- 2024-11-07 MX MX2024013811A patent/MX2024013811A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022550915A5 (enExample) | ||
| JP2023548584A5 (enExample) | ||
| JP2022532169A5 (enExample) | ||
| JP7851349B2 (ja) | Ｓｃｎ１ａ脳症の治療のためのｓｃｎ２ａを標的とするアンチセンスオリゴヌクレオチド | |
| JP2022513719A5 (enExample) | ||
| JP2025165976A5 (enExample) | ||
| JP2025041652A5 (enExample) | ||
| JP2016513976A5 (enExample) | ||
| JP2022519019A (ja) | オリゴヌクレオチド組成物及びその方法 | |
| WO2020157008A1 (en) | Rna-editing oligonucleotides for the treatment of usher syndrome | |
| JP2020534253A5 (enExample) | ||
| CN111373043A (zh) | 用于降低snca表达的化合物和方法 | |
| JP2019525918A5 (enExample) | ||
| JP2009067805A (ja) | 中枢神経系へのポリヌクレオチド薬剤の送達 | |
| JP2009532392A5 (enExample) | ||
| JP2021510511A5 (enExample) | ||
| JPWO2018056442A1 (ja) | 血液脳関門通過型ヘテロ２本鎖核酸 | |
| JP2022527105A5 (enExample) | ||
| WO2016019063A1 (en) | Compositions and methods for modulating tau expression | |
| JP2024521897A5 (enExample) | ||
| JP2023536472A5 (enExample) | ||
| KR20200104347A (ko) | 포스포로디티오에이트 인터뉴클레오시드 연결을 포함하는 갭머 올리고뉴클레오티드 | |
| WO2019181946A1 (ja) | 毒性が軽減した核酸 | |
| JP2021515784A (ja) | 修飾オリゴヌクレオチド及びタウオパチーにおける使用方法 | |
| JP2024543214A (ja) | Ｕｎｃ１３ａ遺伝子転写物のモジュレーターを使用する神経疾患の処置 |